INTRODUCTION
============

As the rate of prevalence and severity of atopic dermatitis (AD) have shown a continuous increase, new therapeutic modalities are being rapidly developed. To date, immunological disorder has been regarded as a main pathogenic factor of AD; however, epidermal barrier function disorder has recently been considered as another main factor causing AD [@B001]-[@B003]. As targeting of epidermal barrier function disorder may treat AD, application of emollients, soaking baths, etc. are now used collaterally with conventional therapeutic modalities such as topical corticosteroid application and antihistamine medication. Because AD is a chronic relapsing disease [@B004],[@B005], development of safer and more convenient treatment modalities with higher compliance is needed.

In Korea, Korean red ginseng (KRG) is used widely and frequently as a health supplement food. Unlike other medications, long term application of KRG is associated with low rates of side effects; therefore, it has lower reluctance and higher compliance. As a result, few patients avoid taking KRG for a long term period.

Bae *et al*. [@B006] and Shin *et al*. [@B007] reported on an antiinflammatory effect of KRG (the steamed root of *Panax ginseng* Meyer, Araliaceae) in a passive cutaneous anaphylaxis reaction, contact dermatitis, and psoriasis in a mouse model trial. Hence, in this article, the authors attempted to conduct an objective investigation of the clinical efficacy of KRG in AD using proven cutting-edge medical engineering and clinical index.

MATERIALS AND METHODS
=====================

Patient characterization
------------------------

Following criteria for diagnosis of Korean AD patients, 30 patients diagnosed as AD were enrolled.

### Inclusion criteria

1\) AD patients who received an explanation of the objective, methods, and efficacy of this clinical trial and who agreed to participation. 2) Patients who had been diagnosed as AD. 3) Age over 7 years old.

### Exclusion criteria

1\) Patients receiving medication for another disease. 2) Patients who were pregnant or breast feeding. 3) Patients who were allergic to this component of KRG. 4) Patients who had been enrolled in another clinical study within 3 months. 5) Patients who were not able to understand the objectives and methods of this clinical trial. 6) Patients who has been treated with other products or medication within 2 weeks before initiation of this clinical study. 7) Other patients considered by the clinician to be inappropriate for participation in this clinical study.

The patient group included a total of 30 patients, 18 female patients and 12 male patients ([Table 1](#T001){ref-type="table"}). Patients' ages ranged from 7 to 41 years old and mean age was 17.3 years old ([Table 2](#T002){ref-type="table"}).

###### 

Sex ratio of atopic patients

  -------- -----------------
           Patient no. (n)
           
  Male     12
  Female   18
  Total    30
  -------- -----------------

###### 

Age of atopic patients

  -------- -------------
           Average age
           
  Male     16.9
  Female   17.8
  Total    17.3
  -------- -------------

### Study design

KRG was prescribed (3 g/day) to 30 AD patients for a period of 16 weeks. Skin investigation was made at 2 cm distal from the ante-cubital wrinkle line before initiation of medication and after 8 weeks and 16 weeks using medical engineering tools. Severity scoring of the atopic dermatitis (SCORAD) index was also performed at the same time. In addition, blood sampling was performed using the same method in order to monitor the difference of serum IgE concentration before and after medication.

Measurement of severity using medical engineering methods
---------------------------------------------------------

Thirty minutes before investigation of skin using medical engineering tools, patients rested under conditions of room temperature constantly ranging between 22℃ to 24℃ and relative humidity ranging between 38% to 42%, which allowed them to adapt to the investigational environment [@B008].

### D-Squame

*D*-Squame (Cuderm, Dallas, TX, USA) is a round-shaped tape with a 22 mm diameter uniformly covered with adhesive material. This tape is made to catch the outermost falling off keratinocytes, which enables quantification of degree of dryness of skin. After compression of the tape for 3 seconds, a Pulnix Tm-7CN monochrome CCD camera (Pulnix America Inc., Sunnyvale, CA, USA) and RGB monitor (PVM 1342Q; Sony Co., Tokyo, Japan) were used for measurement of the distribution and density of attached keratinocytes. This result was analyzed using an image analyzer (AIC Inc., Princeton, NJ, USA), and desquamation index (DI) and scaling index (SI) were calculated using this mathematical formula [@B009],[@B010].

### Evaporimeter

Vertical compression of a 12 mm diameter probe on skin results in development of a water vapor gradient between the surface of the skin and surrounding air. The two humidity sensors in the probe of the evaporimeter (Dermalab; Cortex Technology, Hadsund, Denmark) measure the gradient difference of relative humidity, and, based on this difference, transepidermal water loss (TEWL) can be calculated. The authors measured TEWL 3 times for the same area and the mean value was obtained [@B011].

### Corneometer CM 825

Corneometer CM 825 (Courage-Khazaka, Koln, Germany) is a device that measures degree of skin surface moisture using electrical capacitance of skin surface. Following vertical pressure with a 16 mm diameter probe on skin, measurement of electrical capacitance can be performed, which closely correlates with skin moisture content [@B012]-[@B014]. The authors performed measurements using the corneometer 3 times for the same area and the mean value was obtained.

Measurement of serum IgE
------------------------

Serum IgE was measured by an immunoassay method using Enzygnost-IgE monocloncal (Behringwerke AG, Marburg, Germany). Twenty microliters of IgE standard SI was extracted into test tubes 1 and 2 and 20 μL of SI (IgE standard SI) was extracted into test tubes 3 and 4. Using the same method, 20 μL of IgE control serum was placed in test tubes 5 and 6 and patients' serum was pipetted into test tubes 7 and 8.

After washing all test tubes 3 times with washing solution, 200 μL of chromogen buffer/substrate solution was added and left still in 20℃ to 25℃ for 30 minutes. After 30 minutes, 1,000 μL stopping solution was added and a photometer was used for measurement of serum IgE level [@B015].

Measurement of severity by the SCORAD index
-------------------------------------------

SCORAD index is calculated by the formula presented by The European Task Force on Atopic Dermatitis [@B016]. Reference evaluation systems (0-103)=extent/5(0-20, 19.4%)+3.5×intensity (0-63, 61.2%)+subjective symptoms (0-20, 19.4%). The extent was calculated by "rule of nine", ranging from 0 to 100, and intensity was scored from 0 to 3 in 6 items: erythema, edema/papulation, oozing/crust, excoriation, lichenification, and dryness. Subjective symptoms index, including severity of pruritus and sleep disturbance within the recent 3 days, was acquired using a 10 point scale. Following acquisition of these scores, SCORAD was calculated according to the formula above.

Statistical analysis
--------------------

The SPSS ver. 12.00 (SPSS Inc., Chicago, IL, USA) program was used for all statistical analyses. A *p*-value under 0.05 was considered a significant result. ANOVA or paired t test was also used.

RESULTS
=======

Result of measurement of severity using medical engineering methods
-------------------------------------------------------------------

### D-Squame

Both desquamation index and scaling index showed a decrease after initiation of KRG medication, and, especially at the 16th week after, DI and SI showed a significant decrease (*p*\<0.05) ([Figs. 1](#F001){ref-type="fig"} and [2](#F002){ref-type="fig"}).

![Result of desquamation index (DI) measurement. DI decreased after initiation of Korean red ginseng medication. At the 8th week, no significant decrease was observed; however, at the 16th week, decrease of the DI was significant (\**p*\<0.05).](grosbr-35-149-g001){#F001}

![Result of scaling index (SI) measurement. SI also decreased after initiation of Korean red ginseng medication. At the 8th week, no significant decrease was observed; however, at the 16th week, SI showed a significant decrease (\**p*\<0.05).](grosbr-35-149-g002){#F002}

### Evaporimeter

TEWL value using the evaporimeter ranged from 21.3 to 63.3, and the mean value was 38.8. TEWL value started to decrease after initiation of medication, and at the 16th week, the value showed a significant decrease (*p*\<0.05) ([Fig. 3](#F003){ref-type="fig"}).

![Transepidermal water loss (TEWL) measurement value decreased after taking medication. At the 8th week, no significant decrease was observed; however, at the 16th week, TEWL value showed a significant decrease (\**p*\<0.05).](grosbr-35-149-g003){#F003}

### Corneometer CM 825

Corneometer measurement value ranged within 32.6 to 74.8 and the mean value was 40.0. Skin surface moisture rate increased and was significantly higher at the 16th week (*p*\<0.05) ([Fig. 4](#F004){ref-type="fig"}).

![Results of skin surface moisture measurement showed an increase. At the 8th week, no significant increase was observed; however, it was significantly higher at the 16th week (\**p*\<0.05).](grosbr-35-149-g004){#F004}

Measurement of serum IgE
------------------------

Serum IgE level ranged from 82 to over 5,000 and the mean value was 1049.3. This result correlated with the increased value of serum IgE in AD patients. At the 16th week, mean value was 588.9, which demonstrated a significant diminution of serum IgE level (*p*\<0.05) ([Fig. 5](#F005){ref-type="fig"}).

![Results of serum IgE level measurement. At the 8th week, no significant decrease was observed; however, at the 16th week, mean value was 588.9, which demonstrated significant diminution of serum IgE (\**p*\<0.05).](grosbr-35-149-g005){#F005}

Measurement of severity by the SCORAD index
-------------------------------------------

SCORAD index ranged from 18 to 58, indicating that enrolled patients were included in the moderate to severe AD group. SCORAD index showed a continuous decrease after the 8th and 16th weeks and the diminution at the 16th week was statistically significant (*p*\<0.05) ([Fig. 6](#F006){ref-type="fig"}).

![Results of severity scoring of the atopic dermatitis (SCORAD) index measurement showed a continuous decrease after the 8th and 16th weeks, and diminution of the 16th week was statistically significant (\**p*\<0.05).](grosbr-35-149-g006){#F006}

Safety assessment
-----------------

In this study, no specific side effect, such as gastrointestinal trouble, skin rashes, etc. was observed in the KRG medicated patient group.

DISCUSSION
==========

AD is a chronic recurrent pruritic eczematous condition that usually occurs during infancy [@B017]-[@B020]. It often emerges as an initial signal of atopic march, which progresses to allergic rhinitis and asthma in older age [@B021]. In general, the prevalence and severity of AD decreases with age. However, a recent study comparing prevalence and severity of the last decade with nowadays reported a significant increase of both [@B022]-[@B024].

Many researchers believe that KRG has potential for use as a new therapeutic modality for treatment of dermatologic disease. Our previous study showed that KRG may be helpful in treatment of androgenic alopecia [@B025]. However, there are certain limitations of correlation between AD and KRG. Bae *et al*. [@B006] and Shin *et al*. [@B007] reported on improvement of AD and contact dermatitis by KRG through cytokine regulation in mouse animal models. However, clinical research on the efficacy of KRG in treatment of AD has not yet been reported.

Ginsenosides are the major components of KRG [@B026], and the anti-allergic and anti-inflammatory effects of ginsenoside Rh~1~, anti-allergic effect of ginsenoside Rh~2~, and antiallergic and anti-contact dermatitis activity of KRG and ginsenosides Rg~3~, Rf, and Rh~2~ have already been identified [@B027]-[@B029]. The anti-allergic properties of KRG and ginsenosides have strongly suggested their possibility as potential anti-atopic agents [@B030]. Recently, the effect of topical KRG and ginsenosides in AD has been reported in TNCB-induced AD-like skin lesions in NC/Ngamice. Results showed that application of topical KRG resulted in suppression of mast cell number, TNF-α mRNA, and IL-4 mRNA level, which might lead to a significant decrease of TNCB-induced ear thickening [@B030]. Although this study was both an animal model test and a topical agent application test, unlike our study, the significant decrease of mRNA expression level of TNF-α, IL-4, and mast cell numbers might be correlated with the mechanism of how KRG induces improvement of AD.

In this study, the authors were able to verify the clinical efficacy of KRG using the SCORAD index of skin and TEWL, DI, SI, and skin surface moisture rate using medical engineering methods. In particular, at the 16th week after initiation, all of the indexes and results showed statistically significant improvement. And serum IgE level also showed a significant decrease, which shows accordance with Kobayashi *et al*. [@B031], who reported that 'Hochu-ekki-to', an herbal medicine including ginseng, induced a significantly improved response in the treatment resistant AD patient group, with a significant decrease of serum IgE.

These results suggest that treatment with KRG can result in improved skin barrier function and lower serum IgE. However, as this is a clinical study, the authors think that further basic studies of the mechanism of KRG in AD may be required. In conclusion, the authors demonstrated that KRG may be a helpful functional food for use in management of AD.

This study was supported by the 2009 grant from the Korean Society of Ginseng funded by Korea Ginseng Corporation.
